Seetharama A. Acharya, Ph.D.
Henny Billett, M.D., M.Sc., FACP
Dr. Henny Billett's clinical research interests focus on risk factors for thrombosis and microvascular disease, with emphasis on epidemiological aspects and outcomes research. She studies the effect of race and ethnicity on thrombosis in general and, in particular, investigates the thrombotic and microvascular complications of sickle cell disease.
Eric Bouhassira, Ph.D.
Dr. Eric Bouhassira's research focuses on developing hematopoietic (blood-forming) stem cells that can differentiate into red cells, T cells, platelets, and all other cell types that comprise blood.
Mary Fabry, Ph.D.
Dr. Fabry has used biophysical techniques (infrared spectroscopy, magnetic resonance relaxation, and magnetic resonance imaging) to study enzyme mechanisms, water movement across red cell membranes, and oxygenation and perfusion in transgenic mouse models of hemoglobinopathies.
Paul S. Frenette, MD
Dr. Frenette's laboratory focuses on understanding how hematopoietic stem cells (HSCs) and mature blood cells traffic in vivo.
Ellen W. Friedman, MD
John M. Greally, MB, BCh, PhD
Dr. Greally applies the study of epigenetic regulation of gene expression using high-throughput techniques, and the study of the influence of DNA sequence on epigenetic regulation to the study of human disease. Specific interests include cancer, type II diabetes mellitus, ageing and environmental influences on the epigenome.
Rhoda Hirsch, Ph.D.
Dr. Hirsch's laboratory focuses on the hemoglobinopathy HbE (β26 Glu →Lys) and its related diseases
Dhananjay Kaul, Ph.D.
Dr. Kaul's laboratory focuses on the mechanisms of vascular dysfunction in hemolytic disorders such as sickle cell disease and thalassemia.
Jacob Rand, M.D.
Dr. Rand's laboratory investigates the effects of antiphospholipid (aPL) antibodies on an anticoagulant protein, annexin A5 (previously known as annexin V). The antiphospholipid (aPL) syndrome is an enigmatic autoimmune disorder characterized by thrombosis and/or recurrent spontaneous pregnancy losses that occur in patients who have evidence for antibodies against phospholipid-binding proteins.
Michael B. Stemerman, M.D.
Dr. Stemerman's studies examine the hypothesis that LDL alters the function of the vascular endothelium and this alteration may be an important mechanism for the development of atherosclerosis.